Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ASCO Annual Meeting 2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

2024 ASCO Annual Meeting

Keep up to date with all the top stories and latest evidence with our hub page, including official congress videos and expert takeaways.
ADVANCED SEARCH
Log in
Top
BMC Geriatrics
Published in: BMC Geriatrics 1/2024

Open Access 01-12-2024 | Research

Inflammatory markers and frailty in home-dwelling elderly, a cross-sectional study

Authors: Pia Bålsrud, Stine M. Ulven, Jacob J. Christensen, Inger Ottestad, Kirsten B. Holven

Published in: BMC Geriatrics | Issue 1/2024

Login to get access

Abstract

Background

Low-grade, chronic inflammation during ageing, (“inflammageing”), is suggested to be involved in the development of frailty in older age. However, studies on the association between frailty, using the frailty index definition, and inflammatory markers are limited. The aim of this study was to investigate the relationship between inflammatory markers and frailty index (FI) in older, home-dwelling adults.

Method

Home-dwelling men and women aged ≥ 70 years old, living in South-East Norway were recruited and included in a cross-sectional study. The FI used in the current study was developed according to Rockwood’s frailty index and included 38 variables, resulting in an FI score between 0 and 1 for each participant. Circulating inflammatory markers (IL-6, CRP, IGF-1, cystatin C, cathepsin S, and glycoprotein Acetyls) were analyzed from non-fasting blood samples using ELISA. Whole-genome PBMC transcriptomics was used to study the association between FI score and inflammation.

Results

The study population comprised 403 elderly (52% women), with a median age of 74 years and a mean BMI of 26.2 kg/m2. The mean FI score for the total group was 0.15 (range 0.005–0.56). The group was divided into a frail group (FI score ≥ 0.25) and non-frail group. After adjusting for BMI, age, sex, and smoking in the whole group, IL-6, cathepsin S, cystatin C, and Gp-acetyls remained significant associated to FI score (IL-6: 0.002, 95% CI: 0.001, 0.002, cathepsin S: 6.7e-06, 95% CI 2.44e-06, 0.00001, cystatin C: 0.004, 95% CI: 0.002, 0.006, Gp- Acetyls: 0.09, 95% CI: 0.05, 0.13, p < 0.01 for all), while CRP and IGF-1 were not (0.0003, 95% CI: -00001, 0.0007, p = 0.13, (-1.27e-06), 95% CI: (-0.0003), 0.0003, p = 0.99). There was a significant association between FI score and inflammatory markers, and FI score and monocyte-specific gene expression.

Conclusions

We found an association between FI score and inflammatory markers, and between FI score and monocyte-specific gene expression among elderly subjects above 70 years of age. Whether inflammation is a cause or consequence of frailty and whether the progression of frailty can be attenuated by reducing inflammation remains to be clarified.
Appendix
Available only for authorised users
Literature
1.
2.
3.
Rockwood K, Mitnitski A. Frailty in relation to the accumulation of deficits. The Journals of Gerontology Series A Biological Sciences and Medical Sciences. 2007;62(7):722–7.PubMedCrossRef
4.
Franceschi C, Campisi J. Chronic inflammation (inflammaging) and its potential contribution to age-associated diseases. The Journals of Gerontology Series A Biological Sciences and Medical Sciences. 2014;69 Suppl 1:S4–9.PubMedCrossRef
5.
Franceschi C, Bonafè M, Valensin S, Olivieri F, De Luca M, Ottaviani E, et al. Inflamm-aging. An evolutionary perspective on immunosenescence. Ann N Y Acad Sci. 2000;908:244–54.PubMedCrossRefADS
6.
7.
Cesari M, Penninx BW, Pahor M, Lauretani F, Corsi AM, Rhys Williams G et al. Inflammatory markers and physical performance in older persons: the InCHIANTI study. The journals of gerontology Series A, Biological sciences and medical sciences. 2004;59(3):242–8.
8.
9.
Samson LD, Buisman A-M, Ferreira JA, Picavet HSJ, Verschuren WMM, Boots AM, et al. Inflammatory marker trajectories associated with frailty and ageing in a 20-year longitudinal study. Clin Translational Immunol. 2022;11(2):e1374.CrossRef
10.
Samson LD, Boots AMH, Verschuren WMM, Picavet HSJ, Engelfriet P, Buisman AM. Frailty is associated with elevated CRP trajectories and higher numbers of neutrophils and monocytes. Exp Gerontol. 2019;125:110674.PubMedCrossRef
11.
Ottestad I, Ulven SM, Øyri LKL, Sandvei KS, Gjevestad GO, Bye A, et al. Reduced plasma concentration of branched-chain amino acids in sarcopenic older subjects: a cross-sectional study. Br J Nutr. 2018;120(4):445–53.PubMedCrossRef
12.
Hoogendijk EO, Theou O, Rockwood K, Onwuteaka-Philipsen BD, Deeg DJH, Huisman M. Development and validation of a frailty index in the Longitudinal Aging Study Amsterdam. Aging Clin Exp Res. 2017;29(5):927–33.PubMedCrossRef
13.
Rockwood K, Song X, Mitnitski A. Changes in relative fitness and frailty across the adult lifespan: evidence from the Canadian National Population Health Survey. CMAJ. 2011;183(8):E487–94.PubMedPubMedCentralCrossRef
14.
Williams DM, Jylhava J, Pedersen NL, Hagg S. A Frailty Index for UK Biobank Participants. The journals of gerontology Series A, Biological sciences and medical sciences. 2019;74(4):582–7.
15.
Rockwood K, Blodgett JM, Theou O, Sun MH, Feridooni HA, Mitnitski A, et al. A Frailty Index Based on Deficit Accumulation quantifies mortality risk in humans and in mice. Sci Rep. 2017;7(1):43068.PubMedPubMedCentralCrossRefADS
16.
Rockwood K, Andrew M, Mitnitski A. A comparison of two approaches to measuring frailty in elderly people. The Journals of Gerontology Series A Biological Sciences and Medical Sciences. 2007;62(7):738–43.PubMedCrossRef
17.
Theou O, Brothers TD, Mitnitski A, Rockwood K. Operationalization of frailty using eight commonly used scales and comparison of their ability to predict all-cause mortality. J Am Geriatr Soc. 2013;61(9):1537–51.PubMedCrossRef
18.
Ntanasi E, Yannakoulia M, Kosmidis MH, Anastasiou CA, Dardiotis E, Hadjigeorgiou G, et al. Adherence to Mediterranean Diet and Frailty. J Am Med Dir Assoc. 2018;19(4):315–22e2.PubMedCrossRef
19.
Song X, Mitnitski A, Rockwood K. Prevalence and 10-year outcomes of frailty in older adults in relation to deficit accumulation. J Am Geriatr Soc. 2010;58(4):681–7.PubMedCrossRef
20.
Gordon EH, Reid N, Khetani IS, Hubbard RE. How frail is frail? A systematic scoping review and synthesis of high impact studies. BMC Geriatr. 2021;21(1):719.PubMedPubMedCentralCrossRef
21.
Gjevestad GO, Ottestad I, Biong AS, Iversen PO, Retterstøl K, Raastad T, et al. Consumption of protein-enriched milk has minor effects on inflammation in older adults-A 12-week double-blind randomized controlled trial. Mech Ageing Dev. 2017;162:1–8.PubMedCrossRef
22.
Gjevestad GO, Holven KB, Rundblad A, Flatberg A, Myhrstad M, Karlsen K, et al. Increased protein intake affects pro-opiomelanocortin (POMC) processing, immune function and IGF signaling in peripheral blood mononuclear cells of home-dwelling old subjects using a genome-wide gene expression approach. Genes Nutr. 2019;14:32.PubMedPubMedCentralCrossRef
23.
R.D.C T. R. A language and environment for statistical computing. R Found Stat Comput2016. p. 409.
24.
Newman AM, Steen CB, Liu CL, Gentles AJ, Chaudhuri AA, Scherer F, et al. Determining cell type abundance and expression from bulk tissues with digital cytometry. Nat Biotechnol. 2019;37(7):773–82.PubMedPubMedCentralCrossRef
25.
Soysal P, Stubbs B, Lucato P, Luchini C, Solmi M, Peluso R, et al. Inflammation and frailty in the elderly: a systematic review and meta-analysis. Ageing Res Rev. 2016;31:1–8.PubMedCrossRef
26.
Marcos-Pérez D, Sánchez-Flores M, Proietti S, Bonassi S, Costa S, Teixeira JP, et al. Association of inflammatory mediators with frailty status in older adults: results from a systematic review and meta-analysis. GeroScience. 2020;42(6):1451–73.PubMedPubMedCentralCrossRef
27.
Henry OF, Blacher J, Verdavaine J, Duviquet M, Safar ME. Alpha 1-acid glycoprotein is an independent predictor of in‐hospital death in the elderly. Age Ageing. 2003;32(1):37–42.PubMedCrossRef
28.
Jobs E, Ingelsson E, Risérus U, Nerpin E, Jobs M, Sundström J, et al. Association between serum cathepsin S and mortality in older adults. JAMA. 2011;306(10):1113–21.PubMedCrossRef
29.
Raynaud-Simon A, Lafont S, Berr C, Dartigues JF, Le Bouc Y. Orosomucoid: a mortality risk factor in elderly people living in the community? Clin Nutr. 2002;21(1):45–50.PubMedCrossRef
30.
Otvos JD, Shalaurova I, Wolak-Dinsmore J, Connelly MA, Mackey RH, Stein JH, et al. GlycA: a Composite Nuclear magnetic resonance biomarker of systemic inflammation. Clin Chem. 2015;61(5):714–23.PubMedCrossRef
31.
Hochepied T, Berger FG, Baumann H, Libert C. Alpha(1)-acid glycoprotein: an acute phase protein with inflammatory and immunomodulating properties. Cytokine Growth Factor Rev. 2003;14(1):25–34.PubMedCrossRef
32.
Abernethy DR, Kerzner L. Age effects on alpha-1-acid glycoprotein concentration and imipramine plasma protein binding. J Am Geriatr Soc. 1984;32(10):705–8.PubMedCrossRef
33.
Akinkuolie AO, Pradhan AD, Buring JE, Ridker PM, Mora S. Novel protein glycan side-chain biomarker and risk of incident type 2 diabetes mellitus. Arterioscler Thromb Vasc Biol. 2015;35(6):1544–50.PubMedPubMedCentralCrossRef
34.
Lawler PR, Akinkuolie AO, Chandler PD, Moorthy MV, Vandenburgh MJ, Schaumberg DA, et al. Circulating N-Linked glycoprotein acetyls and longitudinal mortality risk. Circ Res. 2016;118(7):1106–15.PubMedPubMedCentralCrossRef
35.
Wilkinson RDA, Williams R, Scott CJ, Burden RE. Cathepsin S: therapeutic, diagnostic, and prognostic potential. Biol Chem. 2015;396(8):867–82.PubMedCrossRef
36.
Taleb S, Lacasa D, Bastard JP, Poitou C, Cancello R, Pelloux V, et al. Cathepsin S, a novel biomarker of adiposity: relevance to atherogenesis. Faseb j. 2005;19(11):1540–2.PubMedCrossRef
37.
Jobs E, Risérus U, Ingelsson E, Helmersson J, Nerpin E, Jobs M, et al. Serum cathepsin S is associated with serum C-reactive protein and interleukin-6 independently of obesity in elderly men. J Clin Endocrinol Metab. 2010;95(9):4460–4.PubMedCrossRef
38.
Gale CR, Baylis D, Cooper C, Sayer AA. Inflammatory markers and incident frailty in men and women: the English Longitudinal Study of Ageing. Age (Dordr). 2013;35(6):2493–501.PubMedCrossRef
39.
Walker KA, Walston J, Gottesman RF, Kucharska-Newton A, Palta P, Windham BG. Midlife systemic inflammation is Associated with Frailty in later life: the ARIC Study. The journals of gerontology Series A, Biological sciences and medical sciences. 2019;74(3):343–9.
40.
Hart A, Blackwell TL, Paudel ML, Taylor BC, Orwoll ES, Cawthon PM, et al. Cystatin C and the risk of Frailty and Mortality in older men. The Journals of Gerontology: Series A. 2016;72(7):965–70.
41.
Li CL, Ma YJ, Yang C, Hua R, Xie WX, Zhang LX. Association of Cystatin C Kidney function measures with Long-Term Deficit-Accumulation Frailty trajectories and physical function decline. Jama Netw Open. 2022;5(9).
42.
43.
Giovannini S, Onder G, van der Roest HG, Topinkova E, Gindin J, Cipriani MC, et al. Use of antidepressant medications among older adults in European long-term care facilities: a cross-sectional analysis from the SHELTER study. BMC Geriatr. 2020;20(1):310.PubMedPubMedCentralCrossRef
44.
45.
Qu T, Yang H, Walston JD, Fedarko NS, Leng SX. Upregulated monocytic expression of CXC chemokine ligand 10 (CXCL-10) and its relationship with serum interleukin-6 levels in the syndrome of frailty. Cytokine. 2009;46(3):319–24.PubMedPubMedCentralCrossRef
46.
47.
Samson LD, AM HB, Ferreira JA, HS JP, de Rond LGH, de Zeeuw-Brouwer ML, et al. In-depth immune cellular profiling reveals sex-specific associations with frailty. Immun Ageing. 2020;17:20.PubMedPubMedCentralCrossRef
48.
Fried LP, Tangen CM, Walston J, Newman AB, Hirsch C, Gottdiener J et al. Frailty in older adults: evidence for a phenotype. The journals of gerontology Series A, Biological sciences and medical sciences. 2001;56(3):M146–56.
49.
Cesari M, Gambassi G, van Kan GA, Vellas B. The frailty phenotype and the frailty index: different instruments for different purposes. Age Ageing. 2014;43(1):10–2.PubMedCrossRef
Metadata
Title
Inflammatory markers and frailty in home-dwelling elderly, a cross-sectional study
Authors
Pia Bålsrud
Stine M. Ulven
Jacob J. Christensen
Inger Ottestad
Kirsten B. Holven
Publication date
01-12-2024
Publisher
BioMed Central
Published in
BMC Geriatrics / Issue 1/2024
Electronic ISSN: 1471-2318
DOI
https://doi.org/10.1186/s12877-024-04690-2

Other articles of this Issue 1/2024

BMC Geriatrics 1/2024 Go to the issue

Research

Improving diagnostics using extended point-of-care testing during in-home assessments of older adults with signs of emerging acute disease: a prospective observational non-randomised pilot and feasibility study

Research

Development and validation of a nomogram model for all-cause mortality risk in patients with chronic heart failure and atrial fibrillation

Research

Prevalence, perceptions and associated factors of health insurance enrollment among older persons in selected cash grant communities in Ghana: a cross-sectional mixed method

Research

Nurses’ experiences of integrating the salutogenic perspective with person-centered care for older people in Swedish nursing home care: an interview-based qualitative study

Research

Development of the assessment standards of the International Classification of Functioning, Disability, and Health (ICF) Geriatric Core Set through a modified Delphi method

Research

Best practice models of aged-care implemented for First Nations people: a systematic review aligned with the Good Spirit Good Life quality of life principles
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits